Guggenheim Raises ArriVent BioPharma Price Target to $30.00
Guggenheim has increased its price target for ArriVent BioPharma, Inc. from $18.00 to $30.00 per share.
Stocks · News reference
ArriVent BioPharma to Present Phase 1 Data for ARR-217 at ESMO Congress 2026
ArriVent BioPharma announced it will present initial safety and efficacy data from its Phase 1 study of the CDH17-targeted antibody-drug conjugate ARR-217 at the European Society for Medical Oncology (ESMO) Congress 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — ArriVent BioPharma, Inc. (AVBP)
Filed: 2026-10-26 AccNo: 0001104659-26-118550 Size: 220 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
ArriVent BioPharma Announces Initial Phase 1 Results for ARR-217 in Gastrointestinal Cancers
ArriVent BioPharma reported encouraging initial Phase 1 clinical trial results for its CDH17-targeting antibody-drug conjugate, ARR-217, in patients with gastrointestinal malignancies.